Draghia-Akli Ruxandra 4

4 · NOVAVAX INC · Filed Mar 5, 2026

Form 4

Period: 2026-03-02

EVP, Research & Development

Transactions

Exercise/Conversion
Common Stock
2026-03-03+26,667→ 34,876 total
Tax Payment
Common Stock
[F1]
2026-03-03$9.49/sh−11,313$107,360→ 23,563 total
Award
Restricted Stock Units
[F2]
2026-03-02+93,000→ 101,000 total
Exercise: $0.00Exp: 2036-03-02→ Common Stock (93,000 underlying)
Award
Non-Statutory Stock Opotion NQ
[F3]
2026-03-02$9.09/sh+139,500$1,268,055→ 139,500 total
Exercise: $9.09Exp: 2036-03-02→ Common Stock (139,500 underlying)
Disposition to Issuer
Restricted Stock Units
[F4]
2026-03-03−26,667→ 53,333 total
Exercise: $0.00Exp: 2035-03-03→ Common Stock (26,667 underlying)

Footnotes (4)

[F1]Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
[F2]One-third (1/3) of the RSUs subject to this grant under Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date.
[F3]One quarter of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
[F4]One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date.

Signature

/s/ Mark J. Casey, Attorney-in-Fact|2026-03-04

Documents

1 file